Thank you for donating!

You can donate using the following services.


  1. 21.05.20

    Cyclo Therapeutics Inc. Announces Positive Top Line Results from Phase I Trial and Interim Analysis of Phase I/II Trial using Trappsol® Cyclo™ Intravenously to Treat Patients with Niemann-Pick Disease Type C1 (NPC1)

    Read more
  2. 19.05.20

    Cyclo Therapeutics to Hold Call for Patients and Investors Wednesday, May 20 at 4:30 pm EDT

    Read more
  3. 18.05.20

    Cyclo Therapeutics Announces Positive Feedback from European Medicines Agency on its Pivotal Trial Design for Trappsol® Cyclo™ for Niemann-Pick Disease Type C1

    Company reported in March 2020 that FDA had also provided positive feedback on the pivotal trial design...

    Read more
  4. 27.04.20

    Cyclo Therapeutics Closes $2.0 Million Private Placement

    ALACHUA, FL – (BusinessWire) – April 27, 2020 – Cyclo Therapeutics, Inc. (OTCQB: CTDH), a clinical stage biotechnology company that develops cyclodextrin-based products for the treatment of Niemann-Pick Disease Type C (NPC) and Alzheimer’s Disease, today announced that it has closed a private placement of its securities with a group of accredited investors...

    Read more
  5. 04.04.20

    "Time to Talk" (Virtual Elevenses - Webinar Series)

    At this time of social distancing, it has never been more important to stay in touch. Being able to see each other’s faces and to reach out virtually to those we love and miss is essential. This virus may be isolating us but it is also uniting us – more than ever, we are in this together. We are vulnerable together, anxious together, sad together, scared together, and – most importantly - hopeful...

    Read more